- Devic's disease
Name = PAGENAME
DiseasesDB = 29470
ICD10 = ICD10|G|36|0|g|35
ICD9 = ICD9|341.0
MeshID = D009471
Devic's disease, also known as Devic's syndrome or neuromyelitis optica (NMO), is an autoimmune, inflammatory disorder in which a person's own
immune systemattacks the optic nerves and spinal cord. This produces an inflammation of the optic nerve (" optic neuritis") and the spinal cord (" myelitis"). Although inflammation may also affect the brain, the lesions are different from those observed in the related condition multiple sclerosis.cite journal |author=Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA |title=Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression |journal=Arch. Neurol. |volume=63 |issue=7 |pages=964–8 |year=2006 |pmid=16831965 |doi=10.1001/archneur.63.7.964|url=http://archneur.ama-assn.org/cgi/content/full/63/7/964] Spinal cord lesions lead to varying degrees of weakness or paralysisin the legs or arms, loss of sensation, and/or bladder and boweldysfunction. cite journal| last =Wingerchuk| first =DM | authorlink =| coauthors =| title =Neuromyelitis optica| journal =The International MS Journal| volume =13| issue =| pages =42–50| publisher =| date =2006| pmid = 16635421 ]
Devic's disease is a rare disorder which resembles
multiple sclerosis(MS) in several ways, but requires a different course of treatment for optimal results. NMO has also been suggested to be a variant form of acute disseminated encephalomyelitis.cite journal |author=Lennon VA, Wingerchuk DM, Kryzer TJ, "et al" |title=A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis |journal=Lancet |volume=364 |issue=9451 |pages=2106–12 |year=2004 |pmid=15589308 |doi=10.1016/S0140-6736(04)17551-X] [cite journal |author=Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG |title=Brain abnormalities in neuromyelitis optica |journal=Arch. Neurol. |volume=63 |issue=3 |pages=390–6 |year=2006 |pmid=16533966 |doi=10.1001/archneur.63.3.390| url=http://archneur.ama-assn.org/cgi/content/full/63/3/390] The likely target of the autoimmune attack at least in some patients with NMO has been identified. The target is a proteinof the nervous systemcells called aquaporin 4.cite journal |author=Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR |title=IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel |journal=J. Exp. Med. |volume=202 |issue=4 |pages=473–7 |year=2005 |pmid=16087714 |doi=10.1084/jem.20050304|url=http://www.jem.org/cgi/content/full/202/4/473]
The main symptoms of Devic's disease are loss of vision and
spinal cordfunction. As for other etiologies of optic neuritis, the visual impairment usually manifests as decreased visual acuity, although visual fielddefects, or loss of color visionmay occur in isolation or prior to formal loss of acuity. Spinal cord dysfunction can lead to muscle weakness, reduced sensation, or loss of bladder and bowel control. [cite web |url=http://www.mayoclinic.org/devics-disease/symptoms.html |author=Mayo Clinic|title=Devic's Disease Symptoms|accessdate=2008-03-11] The typical patient has an acute and severe spastic weakness of the legs ( paraparesis) or all four limbs ( tetraparesis) with sensory signs, often accompanied by loss of bladder control.
Devic's disease is similar to MS in that the body's
immune systemattacks the myelinsurrounding nerve cells. Unlike standard MS, the attacks are not believed to be mediated by the immune system's T cells but rather by antibodies called NMO-IgG. These antibodies target a proteincalled aquaporin 4 in the cell membranes of astrocytes which acts as a channel for the transport of water across the cell membrane. Aquaporin 4 is found in the processes of the astrocytes that surround the blood-brain barrier, a system responsible for preventing substances in the blood from crossing into the brain. The blood-brain barrier is weakened in Devic's disease, but it is currently unknown how the NMO-IgG immune response leads to demyelination.
Most research into the pathology of Devic's disease has focused on the
spinal cord. The damage in the spinal cord can range from inflammatory demyelination to necrotic damage of the white and grey matter. The inflammatory lesions in Devic's disease have been classified as type II lesions (complement mediated demyelinization), but they differ from MS pattern II lesions in their prominent perivascular distribution. Therefore, the pattern of inflammation is often quite distinct from that seen in MS. [cite journal |author=Lucchinetti CF, Mandler RN, McGavern D, "et al" |title=A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica |journal=Brain |volume=125 |issue=Pt 7 |pages=1450–61 |year=2002 |pmid=12076996 |doi=10.1093/brain/awf151]
Mayo Clinicproposed a revised set of criteria for diagnosis of Devic's disease in 2006. The new guidelines for diagnosis require two absolute criteria plus at least two of three supportive criteria being: [cite journal |author=Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG |title=Revised diagnostic criteria for neuromyelitis optica |journal=Neurology |volume=66 |issue=10 |pages=1485–9 |year=2006 |pmid=16717206 |doi=10.1212/01.wnl.0000216139.44259.74]
BrainMRI not meeting criteria for MS at disease onset
Spinal cordMRI with contiguous T2-weighted signal abnormality extending over 3 or more vertebral segments, indicating a relatively large lesionin the spinal cord
# NMO-IgG seropositive status. The NMO-IgG test checks the existence of antibodies against the
aquaporin 4 antigen.
After the development of the NMO-IgG test, the spectrum of disorders that comprise Devic's disease was expanded. The Devic's disease spectrum is now believed to consist of:
* Standard Devic's disease, according to the diagnostic criteria described above
* Limited forms of Devic's disease, such as single or recurrent events of longitudinally extensive
myelitis, and bilateral simultaneous or recurrent optic neuritis
* Asian optic-spinal MS. This variant can present CNS involvement like MS [cite journal |author=Li Y, Xie P, Lv F, "et al" |title=Brain magnetic resonance imaging abnormalities in neuromyelitis optica |journal=Acta Neurol. Scand. |volume= 0|issue= |pages= 080331054152017|year=2008 |pmid=18384459 |doi=10.1111/j.1600-0404.2008.01012.x]
* Longitudinally extensive
myelitisor optic neuritis associated with systemic auto-immunedisease
* Optic neuritis or myelitis associated with
lesions in specific brain areas such as the hypothalamus, periventricular nucleus, and brainstemcite conference | first =Dean | last =Wingerchuk | title =Neuromyelitis Optica (Devic's Syndrome) | booktitle =2006 Rare Neuroimmunologic Disorders Symposium| date =2006 | url =http://www.myelitis.org/rnds2006/Wingerchuk_NMO_Rare%20Neuroimm_062406_final.pdf| accessdate = 2007-01-05 ]
Whether Devic's disease is a distinct disease or part of the wide spectrum of multiple sclerosis is debated. Devic's disease differs in that it usually has more severe
sequelaeafter an acute episode than in MS, MS infrequently presents as transverse myelitis, and oligoclonal bands in the CSF, as well as white matterlesions on brain MRI, are uncommon in Devic's disease but occur in over 90% of MS patientscite journal |author=Pearce JM |title=Neuromyelitis optica |journal=Spinal Cord |volume=43 |issue=11 |pages=631–4 |year=2005 |pmid=15968305 |doi=10.1038/sj.sc.3101758|url=http://www.nature.com/sc/journal/v43/n11/abs/3101758a.html |format=abstract] . Recently it has been found that antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. [cite journal |author=Jarius S, Franciotta D, Bergamaschi R "et al" | title=Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica |journal=J Neurol Neurosurg Psychiatry. |volume= 79|issue= |pages= 1134|year=2008 |pmid=18270237 |doi=10.1136/jnnp.2007.133330]
Devic's disease has been associated with many systemic diseases, based on anecdoctal evidence of some Devic's disease patients with a comorbid condition. Such conditions include: collagen vascular diseases, autoantibody syndromes,
infections with varicella-zoster virus, Epstein-Barr virus, and HIV, and exposure to clioquinoland antituberculosis drugs. [cite journal |author=Cree BA, Goodin DS, Hauser SL |title=Neuromyelitis optica |journal=Seminars in neurology |volume=22 |issue=2 |pages=105–22 |year=2002 |pmid=12524556 |doi=10.1055/s-2002-36534]
Currently, there is no cure for Devic's disease, but symptoms can be treated. Some patients recover, but many are left with impairment of vision and limbs, which can be severe.
Attacks are treated with short courses of high dosage
intravenous corticosteroids such as methylprednisolone IV. When attacks progress or do not respond to corticosteroid treatment, plasmapheresiscan be an effective treatment. Clinical trials for these treatments contain very small numbers, and most are uncontrolled.
No controlled trials have established the effectiveness of treatments for the prevention of attacks. Many clinicians agree that long term
immunosuppressionis required to reduce the frequency and severity of attacks, while others argue the exact oppositecite journal |author=Poser CM, Brinar VV |title=Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review |journal=Acta Neurol. Scand. |volume=116 |issue=4 |pages=201–6 |year=2007 |pmid=17824894 |doi=10.1111/j.1600-0404.2007.00902.x] . Commonly used immunosuppresant treatments include azathioprine(Imuran) plus prednisone, mycophenolate mofetilplus prednisone, Rituximab, Mitoxantrone, intravenous immunoglobulin(IVIG), and Cyclophosphamide. [cite journal |author=Weinstock-Guttman B, Ramanathan M, Lincoff N, "et al" |title=Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease) |journal=Arch. Neurol. |volume=63 |issue=7 |pages=957–63 |year=2006 |pmid=16831964 |doi=10.1001/archneur.63.7.957|url=http://archneur.ama-assn.org/cgi/content/full/63/7/957] The monoclonal antibody rituximabis under study. [cite journal |author=Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG |title=Neuromyelitis optica |journal=Curr. Opin. Neurol. |volume=20 |issue=3 |pages=255–60 |year=2007 |pmid=17495617 |doi=10.1097/WCO.0b013e32814f1c6b] In 2007, Devic's disease was reported to be responsive to glatiramer acetate[cite journal |author=Gartzen K, Limmroth V, Putzki N |title=Relapsing neuromyelitis optica responsive to glatiramer acetate treatment |journal=Eur. J. Neurol. |volume=14 |issue=6 |pages=e12–3 |year=2007 |pmid=17539924 |doi=10.1111/j.1468-1331.2007.01807.x] and to low-dose corticosteroids. [cite journal |author=Watanabe S, Misu T, Miyazawa I, "et al" |title=Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis |journal= Multiple Sclerosis|volume= 13|issue= |pages= 968|year=2007 |pmid=17623727 |doi=10.1177/1352458507077189]
Normally, there is some measure of improvement in a few weeks, but residual signs and
disabilitymay persist, sometimes severely.
The disease can be monophasic, i.e. a single episode with permanent
remission. However, at least 85% of patients have a relapsing form of the disease with repeated attacks of transverse myelitisand/or optic neuritis. In patients with the monophasic form the transverse myelitis and optic neuritis occur simultaneously or within days of each other. On the other hand, patients with the relapsing form are more likely to have weeks or months between the initial attacks and to have better motor recovery after the initial transverse myelitis event. Relapses usually occur early with about 55% of patients having a relapse in the first year and 90% in the first 5 years. Unlike MS, Devic's disease rarely has a secondary progressive phase in which patients have increasing neurologic decline between attacks without remission. Instead, disabilities arise from the acute attacks.
Approximately 20% of patients with monophasic Devic's disease have permanent visual loss and 30% have permanent paralysis in one or more legs. Among patients with relapsing Devic's disease, 50% have paralysis or blindness within 5 years. In some patients (33% in one study), transverse myelitis in the cervical
spinal cordresulted in respiratory failure and subsequent death. However, the spectrum of Devic's disease has widened due to improved diagnostic criteria, and the options for treatment have improved; as a result, researchers believe that these estimates will be lowered.
prevalenceand incidence of Devic's disease has not been established partly because the disease is underrecognized and often confused with MS. Devic's disease is more common in women than men, with women comprising over 2/3 of patients and more than 80% of those with the relapsing form of the disease.
Devic's disease is more common in Asiatic people than Caucasians. In fact, Asian optic-spinal MS (which constitutes 30% of the cases of MS in
Japan) has been suggested to be identical to Devic's disease(Differences between optic-spinal and classic MS in Japanese patients). In the indigenous populations of tropical and subtropical regions, MS is rare, but when it appears it often takes the form of optic-spinal MS. [cite journal |author=Cabre P, Signate A, Olindo S, "et al" |title=Role of return migration in the emergence of multiple sclerosis in the French West Indies |journal=Brain |volume=128 |issue=Pt 12 |pages=2899–910 |year=2005 |pmid=16183661 |doi=10.1093/brain/awh624]
The majority of Devic's disease patients have no affected relatives, and it is generally regarded as a non-familial condition.
1870, Sir Thomas Clifford Allbuttfirst reported an association between myelitisand an optic nervedisorder. In 1894, Eugène Devicand his PhD. student Fernand Gaultdescribed 16 patients who had lost vision in one or both eyes and within weeks developed severe spastic weakness of the limbs, loss of sensationand often bladder control. They recognized that these symptoms were the result of inflammationof the optic nerve and spinal cord, respectively. [cite book |author= T. Jock Murray |title=Multiple Sclerosis: The History of a Disease |publisher=Demos Medical Publishing |location=New York |year=2005 |pages= |isbn=1888799803 |oclc= |doi=]
Similar instances of
optic neuritisand myelitis were reported, and many believed it constituted a distinct clinical entity. However, some patients had pathologyin other parts of the brain, a feature which was more suggestive of acute disseminated encephalomyelitis(ADEM) or MS.
2004the Mayo Clinicidentified the aquaporin 4protein as the target of the disease and developed a test to aid in the diagnosis of Devic's disease by detection of an antibody, NMO-IgG, in the blood. Some patients with NMO may be seronegative for NMO-IgG whilst some patients with NMO-IgG may still not fulfill clinical criteria for NMO thus serological testing is now an important part of the diagnostic procedure and seropositive and seronegative cases are described in a manner similar to myasthenia gravis. According to the Mayo Clinicreport, this was the first time that a molecular target had been identified for a type of demyelinating inflammatory disease. [cite web |url=http://www.mayoclinic.org/devics-disease/research.html |title=Devic's Disease Research - Mayo Clinic |accessdate=2007-11-22 |format= |work=]
Multiple sclerosis borderline
* [http://www.myelitis.org/devics_disease.htm Devic's Disease (Neuromyelitis Optica)] at myelitis.org
* [http://www.mayoclinic.org/devics-disease/ Devics Disease - Information and treatment options] at
* [http://www.thewaltoncentre.nhs.uk/services/devic_s_disease/default.asp The Walton centre for Neurology and Neurosurgery, Liverpool, United Kingdom] , information for patients and physicians - at NHS
* [http://www.edmus.org/src/proj/studies_nmo.html EDMUS, European Database for Multiple Sclerosis] at edmus.org
* [http://www.nhsdirect.nhs.uk/articles/article.aspx?articleId=2476 NMO / Devic's NHSDirect] - Documentation on the UK National Health Service Database for Medical staff and Patients attending the UK for treatment, it also links to the database gathering data for Mayo Clinic USA and Walton Centre UK - added by MND pp: Dr. Anu Jacob
Wikimedia Foundation. 2010.